Skip to search formSkip to main contentSkip to account menu

ILX 651

Known as: ILX-651, ILX651 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

tasidotin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
Phase I and Pharmacokinetic Study ofTasidotin Hydrochloride ( ILX 651 ) , aThird-Generation Dolastatin-15 Analogue , AdministeredWeekly for 3 Weeks Every 28 Days in Patients with Advanced SolidTumors
Purpose: To determine the safety, tolerability, and pharmacokinetics and to seek preliminary evidence of anticancer activity of… 
2005
2005
Phase I and Pharmacokinetic Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously on Days 1, 3, and 5 Every 3 Weeks in Patients with Advanced Solid Tumors
Purpose: To determine the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), and pharmacokinetics of tasidotin (ILX651… 
2005
2005
ILX651 administered daily for five days every 3 weeks (qdx5dq3w) in patients (pts) with inoperable locally advanced or metastatic melanoma: Phase II experience
7556 Background: ILX65, a synthetic pentapeptide derivative of dolastatin-15, has a unique mechanism of action. At low… 
2005
2005
APhase I Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously Daily for 5 Consecutive Days Every 3Weeks in Patientswith Advanced SolidTumors
Purpose:To determine themaximum tolerated dose, dose-limiting toxicity, andpharmacokinetics of the dolastatin-15 analogue… 
2004
2004
Phase (Ph) I evaluation of the dolastatin analogue synthadotin (SYN-D; ILX651): Pooled data analysis of three alternate schedules in patients (pts) with advanced solid tumors.
3068 Background: SYN-D is a pentapeptide with a unique mechanism of action that potentially differs from microtubule stabilizers… 
2004
2004
Phase II study of synthadotin (SYN-D; ILX651) administered daily for 5 consecutive days once every 3 weeks (qdx5q3w) in patients (Pts) with inoperable locally advanced or metastatic melanoma.
7530 Background: SYN-D is a pentapeptide with a unique mechanism of action that potentially differs from microtubule stabilizers… 
2004
2004
Pharmacokinetics of synthadotin (ILX651), a novel tubulin polymerization inhibitor, in patients with solid tumors
2082 Background: Synthadotin (ILX651) is a pentapeptide with a unique mechanism of action that potentially differs from that of… 
2004
2004
In vitro metabolism and interaction studies with celecoxib and lovastatin.
2122 There is considerable interest in the development of COX-2 (cyclooxygenase-2) and HMG-CoA (3-hydroxy-3-methylglutaryl… 
2004
2004
Pharmacokinetics of synthadotin (ILX651), a novel tubulin polymerization inhibitor, in patients with solid tumors.
2082 Background: Synthadotin (ILX651) is a pentapeptide with a unique mechanism of action that potentially differs from that of… 
2004
2004
527 ILX651 inhibits polymerization of alpha beta III tubulin and is cytotoxic to beta tubulin mutant tumor cell lines that overexpress beta III tubulin
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)